Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hanmi Pharmaceutical and GlaxoSmithKline (GSK) have signed a strategic alliance agreement in Singapore for co-development/marketing of Evidence Based Formulation (EBF) products.
Subscribe to our email newsletter
Under the agreement, Hanmi will be in charge of formulation research, early clinical studies and manufacturing, and GSK will be in charge of late stage clinical studies and registrations.
Both the companies will co-market/co-promote in the Korean and Chinese market, while GSK will be responsible for marketing & sales in rest of the world.
GSK and Hanmi will share clinical development costs based on the agreed terms.
The companies will select products to be developed through joint operation committee (JOT) and joint steering committee (JSC), and the initial launch of the developed product is expected in 2015.